A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone

Trial Profile

A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs TAK 448 (Primary)
  • Indications Testicular disorders
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 08 Dec 2016 Status changed from recruiting to discontinued.
    • 17 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 02 Sep 2015 Study design has been changed from double blind to single blind, number of arms changed from 5 to 4, drug dose has been changed - in cohort 1A: 0.3micrograms to0.1micrograms, cohort 1B: 1.0micrograms to 0.3micrograms, cohort 1C: 3micrograms to 1.0micrograms as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top